The Science of Healing: Alpha-1 Antitrypsin Deficiency
Alpha-1 Foundation research grant funding has supported his work to better understand the clinical implications of liver disease in Alpha-1 patients. Dr. Teckman’s research with the Alpha-1 Liver Initiative focuses on adult Alphas, and his work with the Childhood Liver Disease Research and Education Network (ChiLDReN) focuses on rare pediatric liver disease. In 2022, Dr. Teckman’s work alongside industry partners and A1F funding led to the discovery of a potential treatment for liver disease associated with Alpha-1. It not only stops the production of a malformed protein in the liver but also reverses its previously damaging effects; in essence, healing the liver. The next step in this exciting research is to expand the studies internationally to include more children and patients. Dr. Teckman recently presented at the Grants Awards Reception in October as the keynote speaker and discussed his recent publication in the New England Journal of Medicine, titled “Fazisiran for Liver Disease Associated with Alpha-1 Antitrypsin Deficiency.”
Dr. Teckman’s research findings were recently featured in a video produced by St. Louis University. Scott Santarella, President & CEO of the Alpha-1 Foundation was interviewed for the video highlighting the Foundation’s participation in Alpha-1 Research. Dr. Jeffrey Teckman, SLUCare Pediatric Gastroenterologist at SSM Health Cardinal Glennon Children’s Hospital, helped to develop a treatment for Alpha-1 antitrypsin deficiency.
CLICK HERE TO VIEW: https://www.youtube.com/watch?v=hYmwpCA3cdQ